Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915238 · ClinicalTrials.gov registry record
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
A clinical trial of Age-related Macular Degeneration and AMD, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 52
- Enrollment target
- 2
- Study locations
NCT01915238: Completed study of Age-related Macular Degeneration and AMD, sponsored by National Eye Institute (NEI).
NCT01915238 is a study of Age-related Macular Degeneration and AMD that has completed, run by National Eye Institute (NEI). The registered enrollment target is 52 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01915238, a study of Age-related Macular Degeneration and AMD, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- The Age-Related Eye Disease 2 Study (AREDS2) looked at two eye diseases. These were age-related macular degeneration (AMD) and cataracts. Participants in that study took supplement pills and some participants had additional pictures taken of their eyes. That study is now over. Researchers want to do a follow-up study after participants finish taking the pills, to see if they cause long-term effects on AMD. This study will be combined with follow-up visits of the AREDS2 study if possible. Objectives: \- To learn more about the effect of oral supplements on AMD. Eligibility: \- People who completed the AREDS2 study. Design: * Participants will have up to 2 study visits over 6 18 months. * Each visit will last up to 5 hours. The visits will be combined with annual follow-up visits in the AREDS2 study if possible. * At each visit, participants will undergo an eye exam and photography. * The eye exam includes testing sight, measuring eye pressure, and checking eye movements. To examine the inside of the eye, the pupil will be dilated with eye drops. * Photographs of the inside of the eye may be taken during the eye exam and while the eyes are dilated. * A contact lens may be placed on the eye briefly to look at the retina at the back of the eye.
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
North Carolina
- Duke Univiversity Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-07-16 |
| Est. Completion | 2014-06-20 |
What the finished NCT01915238 record still lists
NCT01915238 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.
NCT01915238 reports a single indexed study location in Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01915238 about?
NCT01915238 is a clinical study titled "Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study". Background: \- The Age-Related Eye Disease 2 Study (AREDS2) looked at two eye diseases. These were age-related macular degeneration (AMD) and cataracts. Participants in that study took supplement pills and some participants had additional pictures taken of their eyes. That study is now over. Resear...
What is the current status of trial NCT01915238?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2013-07-16. Estimated completion is 2014-06-20.
What conditions does trial NCT01915238 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, AMD.
Who is sponsoring clinical trial NCT01915238?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01915238 being conducted?
This trial has 2 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01915238's enrollment target sits among peer trials
52 47th of 74 higher than 28 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI